BeiGene Launches BRUKINSA® (Zanubrutinib) in Canada for Patients with Waldenström’s Macroglobulinemia
Author of the article: BRUKINSA is now commercially available in Canada following approval in March.Canadian patients now have access to the myBeiGene® patient support program. MISSISSAUGA, Ontario — BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced the official…
bubmagApril 8, 2021